Molecular modelling approaches to the design of acetylcholinesterase inhibitors: New challenges for the treatment of Alzheimer's disease

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3131-3140

  Munoz Muriedas J ^a   Lopez, J M ^a   Orozco, Modesto ^a,b   Javier Luque, F ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Molecular modelling; Structure activity relationships

Indexed keywords

1H INDENO[1,2 B]QUINOLIN 10 YLAMINE; ACETOPHENONE DERIVATIVE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AP 2238; CAPROCTAMINE; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; DECAMETHONIUM; DECIDIUM; DICYANODIAMIDE; DONEPEZIL; EDROPHONIUM; GALANTAMINE; GALLAMINE; GUANIDINE DERIVATIVE; HUPERZINE A; HUPRINE; HUPRINE X; META (N,N,N TRIMETHYLAMMONIO)TRIFLUOROACETOPHENONE; NOOTROPIC AGENT; PROPIDIUM IODIDE; QUINOLINE DERIVATIVE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING SITE; CHEMICAL STRUCTURE; DISEASE COURSE; DRUG DESIGN; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BINDING SITES; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4544318524     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383386     Document Type: Review

References (120)

1. Giacobini E. In: Meyer EM, Simpkins JW, Yamamoto J, Crews, FT Eds., Treatment of Dementias: A New Generation of Progress. Advances in Behavioural Biology. Vol. 40, New York, Plenum Press. 1992; 19-34.
2. Brufani M, Filocamo L, Lappa S, Maggi A. New acetylcholinesterase inhibitors. Drugs Fut 1997; 22: 397-410.
3. Muñoz-Torrero D; Camps P. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem 2001; 1: 11-25.
4. Messer WS, Jr. Cholinergic agonists and the treatment of Alzheimer's disease. Curr Top Med Chem 2002; 2:353-8.
5. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275: 630-1.
6. Neve RL, McPhie DL, Chen Y. Alzheimer's disease: a dysfunction of the amyloid precursor protein. Brain Res 2000; 886: 54-66.
7. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann NY Acad Sci 2000; 924: 17-25.
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
9. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7.
10. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of beta-amyloid precursor protein in cell lines. J Neurosc Res 1994; 37: 777-87.
11. Giacobini E. In: Becker R, Giacobini E Eds., Alzheimer Disease: From Molecular Biology to Therapy. Boston, Birkhäuser 1996; 187-204.
12. Giacobini E. Cholinesterase inhibitors stabilise Alzheimer disease. Neuro Res 2000; 25, 1185-90.
13. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91.
14. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-β-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272: 348-61.
15. Johnson G, Moore SW The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem Biophys Res Comm 1999; 258: 758-62.
16. Muñoz FJ, Aldunate R, Inestrosa NC. Peripheral binding site is envolved in the neurotrophic activity of acetylcholinesterase. NeuroReport 1999; 10: 3621-5.
17. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001; 40: 10447-57.
18. Castro A, Martínez A. Peripheral and dual binding site acetylcholinesterase inhibitors: Implications in treatment of Alzheimer's disease. Mini Rev Med Chem 2001; 1: 267-72.
19. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Medic 2002; 8: 126-32.
20. Kaytor MD, Orr HT. The GSK-3β signaling cascade and neurodegenerative disease. Curr Opinion Neurobiol 2002; 12: 275-8.
21. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase 3-β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 1996; 92: 232-41.
22. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, et al. Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999; 58: 1010-9.
23. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147: 58-62.
24. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992; 314: 315-21.
25. Sang H, Lu Z, Li Y, Ru B, Wang W, Chen J. Phosphorylation of tau by glycogen synthase kinase 3β in intact mammalian cells influences the stability of microtubules. Neurosci Lett 2001; 312: 141-4.
26. Takashima A, Yamaguchi H, Noguchi K, Michel G, Ishiguro K, Sato K, et al. Amyloid β peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase 3-β in rat hippocampal neurons. Neurosci Lett 1995; 198: 83-6.
27. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435-9.
28. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medic Res Rev 2002; 22: 373-84.
29. Martinez A, Alonso M, Castro A, Perez CA, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002; 45: 1292-9.
30. Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 2003; 46: 222-36.
31. Olesen PH, Sørensen AR, Ursø B, Kurtzhals P, Bowler AN, Ehrbar U, et al. Synthesis and in vitro characterisation of 1-(4-aminofurazan-3-yl)-5-dialkylanlinomethyl-1H-[1, 2, 3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors. J Med Chem 2003; 46: 3333-41.
32. Kuo GH, Prouty C, DeAngelis A, Shen L, O'Neill DJ, Shah C, et al. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3β inhibitors. J Med Chem 2003; 46: 4021-31.
33. Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology. Massoulié J, Bacou F, Barnard E, Chatonnet A, Doctor BP, Quinn DM (eds.). American Chemical Society: Washington, 1991.
34. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253: 872-79.
35. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman, JL. 3D structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nature Struct Biol 1997; 4: 57-63.
36. Fuxreiter M, Warshel A. Origin of the catalytic power of acetylcholinesterase: Computer simulation studies. J Am Chem Soc 1998; 120: 183-94.
37. Malany S, Sawai M, Sikorski RS, Seravalli J, Quinn DM, Radic Z, et al. Transition state structure and rate determination for the acylation stage of acetylcholinesterase catalyzed hydrolysis of (acetylthio)choline. J Am Chem Soc 2000, 122, 2981-87.
38. 1H-NMR studies. Biochemistry 2001; 40: 5682-90.
39. Millard CB, Koellner G, Ordentlich A, Shafferman A, Silman I, Sussman JL. Reaction products of acetylcholinesterase and VX reveal a mobile histidine in the catalytic triad. J Am Chem Soc 1999; 121: 9983-84.
40. Radic Z, Gibney G, Kawamoto S, MacPhee-Quigley K, Bongiorno C, Taylor P. Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants. Biochemistry 1992; 31: 9760-67.
41. Wlodek ST, Antosiewicz J, Briggs JM. On tile mechanism of action of acetylcholinesterase: The electrostatically induced acceleration of the catalytic acylation step. J Am Chem Soc 1997; 119: 8159-65.
42. Ma JC, Dougherty DA. The cation-π interaction. Chem Rev 1997; 97: 1303-24.
43. Cubero E, Luque FJ, Orozco M. Is polarisation important in cation-π interactions?. Proc Natl Acad Sci USA 1998; 95: 5976-80.
44. Koellner G, Kryger G, Millard CB, Silman I, Sussman JL, Steiner T. Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica. J Mol Biol 2000; 296: 713-35.
45. Henchman RH, Tai K, Shen T, McCammon JA. Properties of water molecules in the active site gorge of acetylcholinesterase from computer simulation. Biophys J 2002; 82: 2671-82.
46. Ripoll DR, Faerman CH, Axelsen PH, Silman I, Sussman JL. An electrostatic mechanism for substrate guidance down the aromatic gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 5128-32.
47. Tan RC, Truong TN, McCammon JA, Sussman JL. Acetylcholinesterase: electrostatic steering increases the rate of ligand binding. Biochemistry 1993; 32: 401-3.
48. Antosiewicz J, McCammon JA, Gilson MK. The determinants of pKas in proteins. Biochemistry 1996; 35: 7819-33.
49. Zhou HX, Briggs JM, McCammon JA. A 240-fold electrostatic rate-enhancement for acetylcholinesterase-substrate binding can be predicted by the potential within the active site. J Am Chem Soc 1996; 118: 13069-70.
50. Wlodek ST, Shen T, McCammon JA. Electrostatic steering of substrate to acetylcholinesterase: Analysis of field fluctuations. Biopolymers 2000; 53: 265-71.
51. Tara S, Elcock AH, Kirchoff PD, Briggs JM, Radic Z, Taylor P, et al. Rapid binding of a cationic active-site inhibitor to wild-type and mutant murine acetylcholinesterase: Brownian dynamics simulation. Biopolymers 1998; 46: 465-74.
52. Radic Z, Kirchoff PD, Quinn DM, McCammon JA, Taylor P. Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. J Biol Chem 1997; 272: 23265-77.
53. Xu Y, Shen J, Luo X, Silman I, Sussman JL, Chen K, et al. How does huperzine A enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations. J Am Chem Soc 2003; 125: 11340-9.
54. Zhou HX, Wlodek ST, McCammon JA. Conformation gating as a mechanism for enzyme specificity. Proc Natl Acad Sci USA 1998; 95: 9280-3.
55. Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry 1999; 38: 122-33.
56. Van Belle D, De María L, Iurcu G, Wodak SJ. Pathways of ligand clearance in acetylcholinesterase by multiple copy sampling. J Mol Biol 2000; 298: 705-26.
57. Gilson MK, Straatsma TP, McCammon JA, Ripoll DR, Faerman CH, Axelsen PH, et al. Open 'back door' in a molecular dynamics simulation of acetylcholinesterase. Science 1994; 263: 1276-8.
58. Tara S, Straatsma TP, McCammon JA. Molecular dynamics of mouse acetylcholinesterase complexed with huperzine A. Biopolymers 1999; 50: 347-59.
59. Enyedy IJ, Kovach IM, Brooks BR. Alternate pathways for acetic acid and acetate ion release from acetylcholinesterase: A molecular dynamics study. J Am Chem Soc 1998; 120: 8043-50.
60. Shafferman A, Ordenlitch A, Barak D, Stein D, Ariel N, Velan B. Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J 1996; 318: 833-40.
61. Ordenlitch A, Barak D, Kronman C, Benschop HP, De Jong LPA, Ariel N, et al. Exploring the active center of human acetylcholinesterase with stereomers of an organophosphorus inhibitor with two chiral centers. Biochemistry 1999; 38: 3055-66.
62. Millard CB, Kryger G, Ordenlitch A, Greenblatt HM, Harel M, Raves ML, et al. Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry 1999; 38: 7032-9.
63. Boutonnet N, Van Belle D, Wodak SJ. Influence of ligand binding on the conformation of Torpedo californica acetylcholinesterase. Theor Chem Acc 2001; 106: 10-21.
64. Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031-5
65. Bourne Y, Taylor P, Radic Z, Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J 2003; 22: 1-12.
66. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): Implications for the design of new anti-Alzheimer drugs. Structure 1999; 7: 297-307.
67. Barril X, Kalko SG, Orozco M, Luque FJ. Rational design of reversible acetylcholinesterase inhibitors. Mini Rev Med Chem 2002; 2: 27-36.
68. Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, et al. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Cryst 2000; D56: 1385-94.
69. Gregor VE, Emmerling MR, Lee C, Moore CJ. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivatives. Bioorg Med Chem Lett 1992; 2, 861-4.
70. Wlodek ST, Antosiewicz J, McCammon JA, Straatsma TP, Gilson MK, Briggs JM, et al. Binding of tacrine and 6-chlorotacrine by acetylcholinesterase. Biopolymers 1996; 38: 109-17.
71. Shutske GM, Pierrat FA, Kapples KJ, Cornfeldt ML, Szewczak MR, Huger FP, et al. 9-Amino-1, 2, 3, 4-tetrahydroacridin-1-ols. Synthesis and evaluation as potential Alzheimer's disease therapeutics. J Med Chem 1989; 32: 1805-13.
72. Jaen JJ, Gregor VE, Lee C, Davis R, Emmerling M. Acetylcholinesterase inhibition by fused dihydroquinazoline compounds. Bioorg Med Chem Lett 1996; 6: 737-42.
73. Recanatini M, Cavalli A, Belluti F, Piazzi L, Rampa A, Bisi A, et al. SAR of 9-amino-1, 2, 3, 4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J Med Chem 2000; 43: 2007-18.
74. Dvir H, Harel M, Barril X, Orozco M, Luque FJ, Muñoz-Torrero D, et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates. Biochemistry 2002; 41: 2970-81.
75. Camps P, Muñoz-Torrero D. Tacrine-Huperzine A hybrids (Huprines): A new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini Rev Med Chem 2001; 1: 163-74.
76. Camps P, El Achab R, Görbig DM, Mortal J, Muñoz-Torrero D, Badia A, et al. Synthesis, in vitro Pharmacology, and Molecular Modelling of Very Potent Tacrine-Huperzine A Hybrids as Acetylcholinesterase Inhibitors of Potential Interest for the Treatment of Alzheimers Disease. J Med Chem 1999; 42: 3227-42.
77. Barril X, Orozco M, Luque FJ. Predicting Relative Binding Free Energies of Tacrine-Huperzine A Hybrids as Inhibitors of Acetylcholinesterase J Med Chem 1999; 42: 5110-19.
78. Camps P, El Achab R, Görbig DM, Morral J, Muñoz-Torrero D, Badia A, et al. New tacrine-huperzine A hybrids (huprines): Highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 2000; 43: 4657-66.
79. Camps P, Cusack B, Mallender WD, El Achab R, Morral J, Muñoz-Torrero D, et al. Huprine X is a novel high affinity inhibitor of acetylcholinesterase that is of interest for the treatment of Alzheimer's disease. Mol Pharmacol 2000; 57: 409-17.
80. Rampa A, Bisi A, Belluti F, Gobbi S, Valenti P, Andrisano V, et al. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease : Molecular modelling, synthesis and kinetic evaluation of 11 H-indeno-[1, 2-b]-quinolin-10-ylamine derivatives. Bioorg Med Chem 2000; 8: 497-506.
81. Marco JL, de los Ríos C, Carreiras MC, Baños JE, Badía A, Vivas NM. Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of new tacrine-like analogues. Bioorg Med Chem 2001; 9: 727-32.
82. 2+ channels and nicotinic receptors. Bioorg Med Chem 2004; in press.
83. Barreiro EJ, Camara CA, Verli H, Brazil-Mas L, Castro NG, Cintra WM, et al. Design, synthesis, and pharmacological profile of novel fused pyrazolo[4, 3-d]pyridine and pyrazolo[3, 4-b][1, 8]naphthyridine isosteres: A new class of potent and selective acetylcholinesterase inhibitors. J Med Chem 2003; 46: 1144-51
84. Pilger C, Bartolucci C, Lamba D, Tropsha A, Fels G. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. J Mol Graphics Model 2001; 19: 288-96.
85. Bartolucci C, Perola E, Pilger C, Fels G, Lamba D. Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins 2001; 42, 182-91.
86. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett 1999; 463: 321-6.
87. Hirasawa Y, Morita H, Shiro M, Kobayashi J. Sieboldine A, a novel tetracyclic alkaloid from Lycopodium sieboldii, inhibiting acetylcholinesterase. Org Lett 2003; 5: 3991-3.
88. Finnelstein BL, Benner EA, Hendrixson MC, Kranis KT, Rauh JJ, Sethuraman MR, et al. Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors. Bioorg Med Chem 2002; 10: 599-613.
89. Taylor P, Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry 1975; 14: 1989-97.
90. Radic Z, Reiner E, Taylor P. Role of the peripheral anionic site on acetylcholinesterase: Inhibition by substrates and coumarin derivatives. Mol Pharmacol 1991; 39: 98-104.
91. Brühlmann C, Ooms F, Carrupt PA, Testa B, Catto M, Leonetti F, et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamino oxidase. J Med Chem 2001; 44: 3195-98.
92. Bernard P, Kireev DB, Chetien JR, Portier PL, Coppet L. Automated docking of 82 N-benzylpiperidine derivatives to mouse acetylcholinesterase and comparative molecular field analysis with 'natural' alignment. J Comput-Aided Mol Des 1999; 13: 355-71.
93. Dimoglo AS, Shvets NM, Tetko IV, Livingstone DJ. Electronic-topological investigation of the structure-acetylcholinesterase inhibitor activity relationship in the series of N-benzylpiperidine derivatives. Quant Struct Act Relat 2001; 20: 31-45.
94. Martinez A, Lanot C, Perez C, Castro A, López-Serrano P, Conde S. Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N-benzylpiperidine aminoacid derivatives. Biorg Med Chem 2000; 8: 731-8.
95. Martínez A, Fernandez E, Castro A, Conde S, Rodríguez-Franco I, Baños JE, et al. N-benzylpiperidine derivatives of 1, 2, 4-thiadiazolidinone as new acetylcholinesterase inhibitors. Eur J Med Chem 2000; 35: 913-22.
96. Andreani A, Cavalli A, Granaiola M, Guardigli M, Leoni A, Locatelli A, et al. Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrooles related to donepezil. J Med Chem 2001; 41: 4011-4.
97. Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG. Aminopyridazines as acetylcholinesterase inhibitors. J Med Chem 1999; 42: 730-41.
98. Contreras JM, Parrot I, Sippl W, Rival YM, Wermuth CG. Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors. J Med Chem 2001; 44: 2707-18.
99. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J Biol Chem 1996; 271: 23646-9.
100. Carlier PR, Han YF, Chow ESH, Li CPL, Wang H, Lieu TX, et al. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999; 7: 351-7.
101. Carlier PR, Chow ESH, Han Y, Liu J, El Yazal J, Pang YP. Heterodimeric tacrine-based acetylcholinesterase inhibitors: Investigating ligand-peripheral site interactions. J Med Chem 1999; 42: 4225-31.
102. Savini L, Campiani G, Gaeta A, Pellerano C, Fattorusso C, Chiasserini L, et al. Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett 2001; 11: 1779-82.
103. Hu MK, Wu LJ, Hsiao G, Yen MH. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J Med Chem 2002; 45: 2277-82.
104. Carlier PR, Du DM, Han Y, Liu J, Pang YP. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg Med Chem Lett 1999; 9: 2335-8.
105. Carlier PR, Du DM, Han YF, Liu J, Perola E, Williams ID, et al. Dimerisation of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew Chem Int Ed 2000; 39: 1775-7.
106. Han YF, Li CPL, Chow E, Wang H, Pang YP, Carlier PR. Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: Contribution of the hydrophobic alkylene tether to monomer and dimer affinities. Bioorg Med Chem 1999; 7: 2569-75.
107. Zeng F, Jiang H, Zhai Y, Zhang H, Chen K, Ji R. Synthesis and acetylcholinesterase inhibitory activity of huperzine A-E2020 combined compound. Bioorg Med Chem Lett 1999; 9: 3279-84.
108. Guillou C, Mary A, Renko DZ, Gras E, Thal C. Potent acetylcholinesterase inhibitors: Design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett 2000; 10: 637-9.
109. Luttman E, Linnemann E, Fels G. Galanthamine as bis-functional ligand for the acetylcholinesterase. J Mol Model 2002; 8: 208-16.
110. Wong DM, Greenblatt HM, Dvir H, Carlier PR, Han YF, Pang YP, et al. Acetylcholinesterase complexed with bivalent ligands related to huperzine A: Experimental evidence for species-dependent protein-ligand complementarity. J Am Chem Soc 2003; 125: 363-373.
111. Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, et al. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J Med Chem 1998; 41: 4186-9.
112. Tumiatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J Med Chem 2003; 46: 954-66.
113. Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurotherapeutics 2001; 1: 61-9.
114. Reyes AE, Perez DR, Alvarez A, Garrido J, Gentry MK, Doctor BP, et al. A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem Biophys Res Commun 1997; 232: 652-5.
115. Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-amyloid aggregation induced by human acetylcholinesterase : inhibition studies. Biochem Pharmacol 2003; 65: 407-16.
116. Rampa A, Bisi A, Valenti P, Recanatini M, Cavalli A, Andrisano V, et al. Acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl methyl]aminoalkoxyheteroary] derivatives. J Med Chem 1998; 41: 3976-86.
117. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, et al. 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: A dual function lead for Alzheimer's disease therapy. J Med Chem 2003; 46: 2279-82.
118. Li Y, Harte WE. A review of molecular modeling approaches to pharmacophore models and structure-activity relationships of ion channel modulators in CNS. Curr Pharm Design 2002; 8(2): 99-110.
119. Lindvall MK. Molecular modeling in cysteine protease inhibitor design. Curr Pharm Design 2002; 8(18): 1673-81.
120. Moro S, Jacobson KA. Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Curr Pharm Design 2002; 8(26): 2401-13.